Drug Overview
Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis. Prolia acts by binding to the receptor activator for nuclear factor kappa B ligand (RANKL), preventing activation of its receptor, RANK. The inhibition of this interaction acts to decrease bone resorption, reducing bone turnover and increasing bone mass and strength by inhibition of osteoclastogenesis and osteoclast activity.
Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis. Prolia acts by binding to the receptor activator for nuclear factor kappa B ligand (RANKL), preventing activation of its receptor, RANK. The inhibition of this interaction acts to decrease bone resorption, reducing bone turnover and increasing bone mass and strength by inhibition of osteoclastogenesis and osteoclast activity.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Prolia: Osteoporosis
List of Figures
Figure 1: Prolia for osteoporosis - SWOT analysis
Figure 2: Drug assessment summary of Prolia for osteoporosis
Figure 3: Drug assessment summary of Prolia for osteoporosis
List of Tables
Table 1: Prolia drug profile
Table 2: Prolia pivotal trial data in osteoporosis
Table 3: Prolia late-phase trial data in osteoporosis
